NEWTON, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 2:00 p.m. E.T. The conference will be held at the St. Regis Hotel in New York.
A live webcast of the event can be accessed under "Events & Presentations" in the Investors section of the Company's website at http://investors.karyopharm.com/events.cfm. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel, first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, viral infection and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit www.karyopharm.com.